Xponance Inc. Buys 88 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Xponance Inc. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 1,873 shares of the company’s stock after purchasing an additional 88 shares during the period. Xponance Inc.’s holdings in Krystal Biotech were worth $338,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Fifth Third Bancorp boosted its holdings in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after buying an additional 105 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $95,000. GAMMA Investing LLC raised its position in shares of Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock valued at $121,000 after purchasing an additional 432 shares during the last quarter. Covestor Ltd raised its position in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Krystal Biotech in the 1st quarter valued at approximately $223,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 1.8%

NASDAQ KRYS opened at $147.49 on Friday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34. The business’s fifty day simple moving average is $136.57 and its 200-day simple moving average is $155.93. The firm has a market cap of $4.26 billion, a PE ratio of 35.45 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analysts’ expectations of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. Research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on KRYS shares. Citigroup reissued a “neutral” rating and set a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. HC Wainwright reissued a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, June 24th. Chardan Capital reissued a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Finally, Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $213.75.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the business’s stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).